Esophageal disease in progressive systemic sclerosis

Current Treatment Options in Gastroenterology

Volumn 11, Issue 1, 2008, Pages 64-69

  Ebert, Ellen C ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CLONIDINE; DILTIAZEM; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; METOCLOPRAMIDE; NICOTINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; POTASSIUM CHLORIDE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; QUINIDINE; TECHNETIUM 99M;

ALCOHOL ABSTINENCE; ANTIREFLUX OPERATION; AUTONOMIC DYSFUNCTION; BARRETT ESOPHAGUS; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL DECISION MAKING; CLINICAL FEATURE; DIET THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DYSPHAGIA; ELECTROSTIMULATION; ENDOSCOPY; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS CANDIDIASIS; ESOPHAGUS DISEASE; ESOPHAGUS MANOMETRY; ESOPHAGUS MOTILITY; ESOPHAGUS PH; ESOPHAGUS SCINTISCANNING; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; GASTROPLASTY; HEARTBURN; HUMAN; LIFESTYLE MODIFICATION; LOWER ESOPHAGUS SPHINCTER PRESSURE; NERVE STIMULATION; PATHOGENESIS; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN FIBROSIS; SMOKING CESSATION; STOMACH EMPTYING; STOMACH FUNDOPLICATION; SYSTEMIC SCLEROSIS;

EID: 58649085227     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-008-0008-8     Document Type: Review

References (48)

1. LeRoy EC, Black C, Fleischemajer R, et al.: Scleroderma (systemic sclerosis): Classification, subsets, and pathogenesis. J Rheumatol 1988, 15: 202-205.
2. Ebert EC: Esophageal disease in scleroderma. J Clin Gastroenterol 2006, 40: 769-775.
3. Treacy WL, Baggenstoss AH, Slocumb CH, Code CF: Scleroderma of the esophagus. A correlation of histologic and physiologic findings. Ann Intern Med 1963, 59: 351-356.
4. Cohen S, Fisher R, Lipshutz W, et al.: The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest 1972, 51: 2663-2668.
5. El-Serag H, Sonnenberg A: Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1997, 92: 52-56.
6. Segel MC, Campbell WL, Medsger TA, Roumm AD: Systemic sclerosis and esophageal adenocarcinoma: Is increased patient screening necessary? Gastroenterology 1985, 89: 486-488.
7. Zamost BJ, Hirschberg J, Ippoliti AF, et al.: Esophagitis in scleroderma: Prevalence and risk factors. Gastroenterology 1987, 92: 421-428.
8. Ebert EC, RuggieroAFM, Seibold JR: Intestinal perforation: a common complication of scleroderma. Dig Dis Sci 1997, 42: 549-553.
9. Wegener M, Adamek RJ, Wedmann B, et al.: Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci 1994, 39: 2209-2215.
10. Maddern GJ, Horowitz M, Jamieson CG, et al.: Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology 1984, 87: 922-926.
11. Mukhopadhyay AK, Graham DY: Esophageal motor dysfunction in systemic diseases. Arch Intern Med 1976, 136: 583-587.
12. Johnson DA, Drane WE, Curran J, et al.: Pulmonary disease in progressive systemic sclerosis: A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989, 149: 589-593.
13. Olive A, Juncosa A, Evison G, et al.: Air in the oesophagus: a sign of oesophageal involvement in systemic sclerosis. Clin Rheumatol 1995, 14: 319-321.
14. Clements PJ, Kadell B, Ippoliti A, Ross M: Esophageal motility in progressive systemic sclerosis: Comparison of cine-radiographic and manometric evaluation. Dig Dis Sci 1979, 24: 639-644.
15. Klein HA, Wald A, Graham TO, et al.: Comparative studies of esophageal function in systemic sclerosis. Gastroenterology 1992, 102: 1551-1556.
16. Murphy JR, McNally P, Peller P, et al.: Prolonged clearance is the primary abnormal reflux parameter in patients with progressive sclerosis and esophagitis. Dig Dis Sci 1992, 37: 833-841.
17. Stentoft P, Hendel L, Aggestrup S: Esophageal manometry and pH-probe monitoring in the evaluation of gastroesophageal reflux in patients with progressive systemic sclerosis. Scand J Gastroenterol 1987, 22: 499-504.
18. Weber P, Ganser G, Frosch M, et al.: Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. J Rheumatol 2000, 27: 2692-2695.
19. Orringer MB, Dabich L, Zarafonetis CJ, et al.: Gastroesophageal reflux in esophageal scleroderma: Diagnosis and implications. Ann Thorac Surg 1976, 22: 120-130.
20. Carola F, Bianchi PA, Basilisco G: Intraesophageal pH monitoring during acid infusion in patients with systemic sclerosis. Dig Dis Sci 1999, 44: 1716-1720.
21. Baron M, Arzoumanian A: Radionuclide esophageal transit studies in progressive systemic sclerosis: An analysis of longitudinal data. J Rheumatol 1991, 18: 1837-1840.
22. Akesson A, Gustafson T, Wollheim F, et al.: Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis. Scand J Rheumatol 1987, 16: 291-299.
23. Villadsen GE, Storkholm JH, Hendel L, et al.: Impedance planimetric characterization of esophagus in systemic sclerosis patients with severe involvement of esophagus. Dig Dis Sci 1997, 42: 2317-2326.
24. Tutuian R, Castell DO: Combined multichannel intraluminal impedance and manometry clarifies esophageal function abnormalities: Study in 350 patients. Am J Gastroenterol 2004, 99: 1011-1019.
25. Miller LS, Liu JB, Klenn PJ, et al.: Endoluminal ultrasonography of the distal esophagus in systemic sclerosis. Gastroenterology 1993, 105: 31-39.
26. Lock G, Holstegee A, Lang B, et al.: Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997, 92: 763-771.
27. Lock G, Zeuner M, Straub RH, et al.: Esophageal manometry in systemic sclerosis: Screening procedure or confined to symptomatic patients? Rheumatol Int 1997, 17: 61-66.
28. Sallam H, McNParney TA, Chen JD: Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis. Aliment Pharmacol Ther 2006, 23: 691-712.
29. Shoenut JP, Kerr P, Micflikier AB, et al.: The effect of nasal CPAP on nocturnal reflux in patients with aperistaltic esophagus. Chest 1994, 106: 738-741.
30. Kahan A, Bour B, Couturier D, et al.: Nifedipine and esophageal dysfunction in progressive systemic sclerosis. A controlled manometric study. Arthritis Rheum 1985, 28: 490-495.
31. Jean F, Aubert A, Bloch F, et al.: Effects of diltiazem versus nifedipine on lower esophageal sphincter pressure in patients with progressive systemic sclerosis. Arthritis Rheum 1986, 29: 1054-1055.
32. Hendel L, Aggestrup S, Stentoft P: Long-term ranitidine in progressive systemic sclerosis (scleroderma) with gastroesophageal reflux. Scand J Gastroenterol 1986, 21: 799-805.
33. Petrokubi RJ, Jeffries GH: Cimetidine versus antacid in scleroderma with reflux esophagitis. A randomized double-blind controlled study. Gastroenterology 1979, 77: 691-695.
34. Hendel L, Hage E, Hendel J, Stentoft P: Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992, 6: 565-577.
35. Hage E, Hendel L, Gustafsen J, Hendel J: Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole. Eur J Gastroenterol Hepatol 2003, 15: 781-789.
36. Hendel L: Hydroxyproline in the oesophageal mucosa of patients with progressive systemic sclerosis during omeprazole-induced healing of reflux oesophagitis. Aliment Pharmacol Ther 1991, 5: 471-480.
37. Johnson DA, Drane WE, Curran J, et al.: Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Arch Intern Med 1987, 147: 1597-1601.
38. Ramirez-Mata M, Ibanez G, Alarcon-Segovia D: Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients with PSS. Arthritis Rheum 1977, 20: 30.
39. Wang SJ, La JL, Chen DY, et al.: Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 2002, 21: 43-45.
40. Kahan A, Chaussade S, Gaudric M, et al.: The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: A controlled manometric study. Br J Clin Pharmacol 1991, 31: 683-687.
41. Kaada B: Successful treatment of esophageal dysmotility and Raynaud's phenomenon in systemic sclerosis and achalasia by transcutaneous nerve stimulation. Increase in plasma VIP concentration. Scand J Gastroenterol 1987, 22: 1137-1146.
42. Mearin F, Zacchi P, Armengol JR, et al.: Effect of transcutaneous nerve stimulation on esophageal motility in patients with achalasia and scleroderma. Scand J Gastroenterol 1990, 25: 1018-1023.
43. Maeda M, Ichiki Y, Sumi A, Mori S: A trial of acupuncture for progressive systemic sclerosis. J Dermatol 1988, 15: 133-140.
44. Dessein PH, Joffe BI, Metz RM, et al.: Autonomic dysfunction in systemic sclerosis: Sympathetic overactivity and instability. Am J Med 1992, 93: 143-150.
45. Orringer MB, Orringer JS, Dabich L, Zarafonetis CJ: Combined Collis gastroplasty-fundoplication operations for scleroderma reflux esophagitis. Surgery 1981, 90: 624-630.
46. Poirier NC, Taillefer R, Topart P, Duranceau A: Antireflux operations in patients with scleroderma. Ann Thorac Surg 1994, 58: 66-72; discussion 72-73.
47. O'Leary JP, Hollenbeck JI, Woodward ER: Surgical treatment of esophageal stricture in patients with scleroderma. Am Surg 1975, 41: 131-135.
48. Mansour KA: 1988: Surgery for scleroAerma of the esophagus: a 12-year experience. Updated in 1995. Ann Thorac Surg 1995, 60:227.